Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL
MAIC Analysis Shows PFS Favorability With Zanubrutinib vs Acalabrutinib/Venetoclax in CLL
Isa-KRd Yields Prolonged MRD Negativity vs KRd in Newly Diagnosed Myeloma
Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple Myeloma